Recent deal announcements are giving evidence to Chinese companies being at the heels of their western counterparts in terms of developing innovative treatments. With transaction deals doubling 2019 to the tune of $3.1B USD (from Jan-June 2020), all eyes are on China. What is driving this revolution in Chinese biotech? How has the wider community responded? Join experts from pharma, biotech and venture as they discuss what factors are contributing to this radical transformation.